A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1
- 저널
- JOURNAL OF CONTROLLED RELEASE133(3) · pp.172 · 2009
- 피인용
- Web of Science 60
- JCR IF
- JCR 2008 5.69
- ISSN
- 0168-3659
저자
- Jin, Cheng-Hao제1저자성균관대학교, Drug Targeting Lab, Coll Pharm, KO
- Chae, Su Young성균관대학교, Drug Targeting Lab, Coll Pharm, KO
- Son, Sohee성균관대학교, Drug Targeting Lab, Coll Pharm, KO
- Kim, Tae Hyung성균관대학교, Drug Targeting Lab, Coll Pharm, KO
- Um, Key An성균관대학교, Drug Targeting Lab, Coll Pharm, KO
- 윤유석부산대학교, 약학대학, 약학부, 제약학전공, KO
- Lee, Seulki한국과학기술연구원, Biomed Res Ctr, KO
- Lee, Kang Choon성균관대학교, Drug Targeting Lab, Coll Pharm, KO
초록
An orally active glucagon-like peptide-1 (GLP-1) formulation would have great advantages over conventional injectable therapies for the treatment of diabetic patients. Because GLP-1 absorption in the intestine is restricted by its natural physiological characteristics, biotinylated exendin-4 analogues might useful as orally active GLP-1 receptor agonists. Three different biotinylated exendin-4 analogues, Lys(27)-Biotin-Exendin-4 (MB1-Ex-4), Lys(12)-Biotin-Exendin-4 (MB2-Ex-4), and Lys(12,) (27)-Biotin-Exendin-4 (DB-Ex-4) were prepared, and their biological activities and enzymatic stabilities were studied in vitro. The hypoglycemic effects and pharmacokinetics of these analogues after oral administration were evaluated in db/db mice and Sprague-Dawley rats, respectively. These biotinylated exendin-4 analogues preserved GLP-1 receptor binding affinity and stimulated insulin secretion in RIN-m5F murine insulinoma cells and in isolated rat islets, respectively, and were as potent as exendin-4. In particular, DB-Ex-4 showed 9.0-fold better stability against rat intestinal fluid than exendin-4. When 0.1, 1, and 10 mu g/mouse of DB-Ex-4 were orally administered, mean total hypoglycemic degrees (HGD) were increased by 36.8 +/- 1.2, 46.9 +/- 1.8, and 54.3 +/- 4.5%, respectively, whereas 1 mu g/mouse of native exendin-4 showed an increase of 8.8 +/- 7.3%. This study demonstrates that biotinylated exendin-4 analogues are absorbed in the intestine and that they have biological efficacies of exendin-4. Furthermore, it indicates that biotinylated exendin-4 analogues could be used as potential oral antidiabetic agent for the treatment of type 2 diabetes. (C) 2008 Elsevier B.V. All rights reserved.
식별자
- WoS UID
- 000263700000002



로그인
연구물 목록으로